LCM
XFOR icon

Lazari Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Lazari Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-333
Closed -$2.36K – 162
2025
Q1 		$2.36K Hold
333
– – ﹤0.01% 155
2024
Q4 		$7.34K Sell
333
-100
-23% -$1.59K ﹤0.01% 151
2024
Q3 		$8.7K Buy
433
+33
+8% +$689 ﹤0.01% 156
2024
Q2 		$6.96K Buy
400
+67
+20% +$2.19K ﹤0.01% 143
2024
Q1 		$13.9K Hold
333
– – 0.01% 125
2023
Q4 		$8.38K Buy
+333
New +$8.1K ﹤0.01% 123

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lazari Capital Management's XFOR Position: Q2 2025 in Review

Lazari Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 333 shares — an estimated $2.36K sold.

Lazari Capital Management first reported a position in XFOR in Q4 2023 and held it in 6 quarters. The position peaked at $13.9K in Q1 2024. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • Lazari Capital Management reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Lazari Capital Management sold 333 X4 Pharmaceuticals shares in Q2 2025, an estimated $2.36K.
  • Lazari Capital Management first reported a position in X4 Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Lazari Capital Management's X4 Pharmaceuticals position peaked at $13.9K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Lazari Capital Management's 13F filing for Q2 2025, filed 17 Jul 2025.